31Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Malaysia
Neuroscience Intelligence
Malaysia neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #45 of 50 · Data maturity A · Research score 27.5 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:34 UTC.
7Recruiting trials
26Publications
26Institutions
Executive interpretation
Malaysia ranks #45 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC73 recruiting
Bayer22 recruiting
AbbVie20 recruiting
Boehringer Ingelheim20 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.20 recruiting
University of Malaya20 recruiting
Eidos Therapeutics, a BridgeBio company11 recruiting
GlaxoSmithKline10 recruiting
Janssen Research & Development, LLC10 recruiting
Astellas Pharma Inc10 recruiting
Disease activity
Parkinsons10trials
Epilepsy5trials
Stroke3trials
Alzheimers2trials
Dementia Other2trials
Depression2trials
Schizophrenia1trials
Other Neurology1trials
Research institutions
University Malaya Medical CentreOpenAlexlinked institution
Sultan Zainal Abidin UniversityOpenAlexlinked institution
IMU UniversityOpenAlexlinked institution
AIMST UniversityOpenAlexlinked institution
Southern University CollegeOpenAlexlinked institution
Taylor's UniversityOpenAlexlinked institution
University of Kuala LumpurOpenAlexlinked institution
Monash University MalaysiaOpenAlexlinked institution
Tropical Infectious Diseases Research & Education CentreOpenAlexlinked institution
National University of MalaysiaOpenAlexlinked institution
Clinical evidence trail
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06563895Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantRECRUITING
NCT05457283A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and ProteinuriaRECRUITING
NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)ACTIVE_NOT_RECRUITING
NCT05196035A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and ProteinuriaACTIVE_NOT_RECRUITING
NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)ACTIVE_NOT_RECRUITING
NCT07256093The Effectiveness of Acceptance and Commitment Therapy (ACT) on Dysfunctional Attitudes and Difficulties in Emotion Regulation Among University Students in MalaysiaCOMPLETED
NCT06036836Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)COMPLETED
NCT05211947A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX StudyTERMINATED
NCT05064059A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)COMPLETED
NCT05034107Effects of Diffused Ylang-Ylang Essential Oil Amongst Older Persons With DementiaCOMPLETED
Research evidence trail
PUBMEDBrain network alterations underlying cue reactivity and craving in abstinent methamphetamine users: a systematic review of functional MRI findings.2026-12-01
PUBMEDIntegrative transcriptomic and machine learning analysis identifies S100A8 as a key hub bridging peripheral inflammation and synaptic deficits in schizophrenia.2026-11-01
PUBMEDSuspected reversible cerebral vasoconstriction syndrome following ethinylestradiol-containing oral contraceptive use in a patient with migraine.2026-08-19
PUBMEDClinical characteristics, functional impact and caregivers' priorities in Malaysian children with dystonic cerebral palsy.2026-08-01
PUBMEDSurgical Third Nerve Palsy as a Rare Presentation of Tuberculous Meningitis: Early Clinical Judgement and Advanced Imaging.2026-06-01
PUBMEDImpact of migraine on quality of life and disability: a matched cross-sectional comparative study in a tertiary hospital in Malaysia.2026-01-01
OPENALEXMicrobiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases2024-02-15
OPENALEXVarious Natural and Anthropogenic Factors Responsible for Water Quality Degradation: A Review2021-09-27
OPENALEXSpinal Cord Injury: Pathophysiology, Multimolecular Interactions, and Underlying Recovery Mechanisms2020-10-13
OPENALEXThe E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges2019-09-20
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.